iga — Blog — NephJC

April 14, 2025

Background

swapnil hiremath

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

March 23, 2025

Background

Brian Rifkin

KDIGO 2025 ADPKD Guidelines Review

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.

March 11, 2025

Background

Cristina Adriana Popa

REGENCY: A B-Cell Super Destroyer in Lupus

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

February 24, 2025

Background

Cristina Adriana Popa

Hunting Primary Hyperaldosteronism: are MRAs a ...

This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions

February 10, 2025

Background

Brian Rifkin

Undercover Aldosterone

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

iga

swapnil hiremath

April 9, 2024

Background

Healing, Hype, or Harm: The NefIgArd trial

swapnil hiremath

April 9, 2024

Background

Healing, Hype, or Harm: The NefIgArd trial

This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?

joel topf

February 5, 2024

Future Topic

🤔 GWAS in IgA Nephropathy

joel topf

February 5, 2024

Future Topic

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy (Kiryluk, Nature Genetics 2023)

joel topf

February 5, 2024

Future Topic

🤔 Sibeprenlimab in IgA Nephropathy

joel topf

February 5, 2024

Future Topic

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (Mathur, NEJM 2024)

joel topf

February 5, 2024

Future Topic

🤔 Sparsentan in IgA Nephropathy

joel topf

February 5, 2024

Future Topic

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Rovin, Lancet 2023)